The ins and outs of susceptibility testing for new b-lactam/b-lactamase inhibitor combinations for gram-negative organisms
JavaScript is disabled for your browser. Some features of this site may not work without it.
We are excited to announce that the repository will soon undergo an upgrade, featuring a new look and feel along with several enhanced features to improve your experience. Please be on the lookout for further updates and announcements regarding the launch date. We appreciate your support and look forward to unveiling the improved platform soon.
| dc.contributor.author | Dingle, Tanis
|
|
| dc.contributor.author | Pitout, Johann D.D.
|
|
| dc.date.accessioned | 2022-10-27T04:46:37Z | |
| dc.date.available | 2022-10-27T04:46:37Z | |
| dc.date.issued | 2022-07 | |
| dc.description.abstract | Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam are among the newest b-lactam/b-lactamase inhibitors (BL/BLIs) introduced to the North American antibiotic market. All have broad Gram-negative activity, including against certain carbapenemases. Despite this, susceptibility testing is warranted due to variable activity against certain b-lactamases (e.g., oxacillinases) and the presence of acquired resistance mechanisms in some isolates. Here, we discuss what we know about these new antimicrobial agents and how to navigate implementation of susceptibility testing and reporting of these agents in clinical laboratories. | en_US |
| dc.description.department | Medical Microbiology | en_US |
| dc.description.uri | https://journals.asm.org/journal/jcm | en_US |
| dc.identifier.citation | Dingle, T.C. & Pitout, J. The Ins and Outs of Susceptibility Testing for New β-Lactam/β-Lactamase Inhibitor Combinations for Gram-Negative Organisms. Journal of Clinical Microbiology 2022 Jul 20;60(7):e0080721. doi: 10.1128/jcm.00807-21. | en_US |
| dc.identifier.issn | 0095-1137 (print) | |
| dc.identifier.issn | 1098-660X (online) | |
| dc.identifier.other | 10.1128/jcm.00807-21 | |
| dc.identifier.uri | https://repository.up.ac.za/handle/2263/87986 | |
| dc.language.iso | en | en_US |
| dc.publisher | Journal of Clinical Microbiology | en_US |
| dc.rights | © 2022 American Society for Microbiology. All Rights Reserved. | en_US |
| dc.subject | Antimicrobial activity | en_US |
| dc.subject | Antimicrobial susceptibility testing | en_US |
| dc.subject | B-lactamases | en_US |
| dc.subject | B-lactams | en_US |
| dc.subject | Carbapenemase | en_US |
| dc.subject | Antimicrobial resistance (AMR) | en_US |
| dc.subject | B-lactam/b-lactamase inhibitors (BL/BLIs) | en_US |
| dc.title | The ins and outs of susceptibility testing for new b-lactam/b-lactamase inhibitor combinations for gram-negative organisms | en_US |
| dc.type | Article | en_US |
